James M. Wilson and the art of starting again

In 2024, James M. Wilson announced that he was leaving the University of Pennsylvania to found two companies. He had arrived at Penn in 1993. Thirty-one years is enough time for an office to become a habitat, for colleagues to become part of the furniture of daily life, and for an institutional title to feel inseparable from its owner. Wilson was changing the arrangement.

The new names were GEMMA Biotherapeutics, usually shortened to GEMMABio, and Franklin Biolabs. He would lead the first as chief executive and chair the second. The two businesses began operating on October 1, 2024. They emerged from functions of the university program he had directed, taking an established body of work into a different organizational setting.

There is a familiar version of the academic founder’s story: a young researcher sees a commercial opening and leaves campus. Wilson’s version begins much later. He already had decades of research, company formation and institutional leadership behind him. The interesting decision was what to do when experience stopped providing a dependable route forward.

His answer involved two separate companies, a continuing base in the Philadelphia area and an international set of relationships. The lab work would carry on. The machinery around it would change. At a point when a career might reasonably be organized into retrospective chapters, Wilson was adding new letterhead.

A business model reaches its sell-by date

Wilson had helped establish businesses long before GEMMABio. His record includes Genovo, REGENXBIO, Passage Bio and Scout Bio. These were separate ventures, rather than a single company repeatedly renamed. Across his academic career, he had become accustomed to the work of connecting research with people prepared to finance and develop it.

The commercial sequence he described was straightforward. Advance the work. Increase the company’s value. Bring in more investors. Eventually, sell to a large pharmaceutical company. Each stage helped make the next one possible. A prospective buyer at the end gave the earlier investors a reason to participate.

By 2025, Wilson was explaining why he had moved away from depending on that sequence. Large pharmaceutical companies had lost interest in the area in which he worked. The expected exit became harder to see. He described the resulting loss of investment momentum as a shutdown.

That is a sentence about the plumbing of a business. Liquidity sounds abstract until its absence determines which projects can continue. Wilson’s response was to seek a structure that did not depend on a large company arriving later to complete the commercial journey. GEMMABio would pursue its own partnerships and a different route to building an operating business.

“When that avenue of liquidity evaporated, the whole thing shut down.”

James M. Wilson · May 2025

Two companies, two sets of jobs

The split between GEMMABio and Franklin Biolabs was deliberate. GEMMABio took the research and innovation role. Franklin became a contract research organization, providing services and production capabilities to other companies. They would operate independently. Wilson’s own responsibilities crossed the boundary: executive leadership on one side, chairmanship on the other.

It is a useful distinction because “a scientist starts a company” can conceal several businesses under one sentence. Developing a company’s own projects demands one set of decisions. Providing specialized work for outside customers demands another. Wilson’s arrangement gave those functions separate organizations, each with its own commercial purpose.

The transition also had a human dimension. At the announcement, most employees of the Penn program were to be offered positions in one of the new companies. Additional hiring was planned. Those were intentions stated at the outset, rather than a final count of who moved. Still, the plan made clear that this was a transfer of working capabilities as well as an executive’s change of employer.

Both companies would conduct their global work from greater Philadelphia. Their announced network reached the United Kingdom, Brazil and South Korea. The geography joined continuity with expansion: a regional home for a team whose relationships extended abroad. Starting again did not require pretending that the previous thirty years had never happened.

The people who make a new name work

Wilson’s current organization contains several connections to his Penn years. Monique Molloy, GEMMABio’s chief corporate affairs officer, began working in the field as he was establishing his university research effort. She later held senior administrative roles in the Penn program and center he led. At GEMMABio, her responsibilities include communications, people, relationships and strategic planning.

Ramon Salsas Escat, the chief business officer, also came through the Penn program, joining its business development work in 2016. He subsequently held a senior role at G2Bio. His remit at GEMMABio includes alliances, business development, legal matters and intellectual property. These are the negotiations and agreements through which a research organization acquires a commercial shape.

Juliette Hordeaux serves as chief scientific officer. Her earlier work included leading or jointly leading programs in Wilson’s Penn organization. She now oversees discovery and research direction at GEMMABio. The continuity across these appointments is specific: different members of the team carry scientific, administrative and commercial experience into the new company.

Annalisa Jenkins chairs GEMMABio’s board. Wilson is therefore working within a structure that includes an executive team and board leadership, alongside his own founder role. A company biography can fit one person into a photograph. The operating organization requires rather more people than the photograph has room for.

The money has more than one job

On December 23, 2024, GEMMABio announced a $34 million seed round. Double Point Ventures, Bioluminescence Ventures and Earlybird Venture Capital co-led it, with additional backing from Savanne Life Sciences. This was financing for the new company’s operations and work, secured within months of its formal launch.

An earlier agreement with Brazil’s Oswaldo Cruz Foundation, known as Fiocruz, involved a different kind of commitment: up to $100 million tied to a collaboration. That figure should retain its “up to.” It described the potential scope of an agreement, rather than a second seed round or a statement that the entire amount was already in GEMMABio’s bank account.

The distinction matters to Wilson’s story. Venture financing and an international institutional partnership are different relationships, with different responsibilities. His new approach brought both into the company’s early development. The business was being assembled through a combination of investors and organizations that could become long-term partners.

Wilson had discussed the need for different commercial arrangements before leaving Penn. In a September 2022 conversation in Philadelphia, he called for “more efficient businesses” and “simpler and better commercial models.” The 2024 companies gave organizational form to a concern he had already expressed in public. His departure was a visible event in a longer discussion about how to organize the work.

Before Philadelphia, there was Albion

Wilson is a native of Grosse Pointe, Michigan. He graduated from Albion College in 1977 with a bachelor’s degree in chemistry, then earned an M.D. and a doctorate in biological chemistry at the University of Michigan in 1984. His subsequent training took him to Massachusetts General Hospital and, from 1986 to 1988, the Whitehead Institute at MIT.

That sequence puts a small liberal arts college at the beginning of a career later associated with a large research university. Albion remained part of his life. In 2018, Wilson and his wife, Lisa, an Albion graduate from the class of 1979, gave $5.1 million to establish the Lisa and James Wilson Institute for Medicine.

The gift supported undergraduate preparation, with changes to curriculum and opportunities for students. The college’s account of the initiative included faculty from chemistry, biology, sociology, mathematics and psychological science. For a biography dominated by specialized research, that range is an instructive detail: the educational project brought multiple disciplines into the same conversation.

Four years later, Wilson returned as Albion’s commencement speaker. The 2022 program placed his address between the honorary degree presentation and a choir selection. An alumnus who had once been among the students facing the platform was now on it. The return offers a quieter counterpoint to the company launches: one institution had given him a beginning, and he was helping prepare beginnings for others.

A next chapter with more names in it

The company-building continued after the original pair. In October 2025, GEMMABio announced the launch of Rare Therapeutics, Inc., known as RareTx, as an affiliate. The new entity would draw on relationships in Brazil and Abu Dhabi. Whatever the individual projects, the organizational choice was consistent with Wilson’s recent approach: give a defined body of work a structure built for its particular commercial requirements.

In July 2026, GEMMABio announced an ARPA-H funding award and a partnership with Profluent Bio, an AI laboratory for biology. The collaboration brought another organization’s computational capabilities into Wilson’s company’s research effort. It is a recent addition to the network around him, and a reminder that his present role involves choosing collaborators as well as setting direction inside his own business.

These announcements describe work in progress. They establish new companies, funding and partnerships; they do not settle how the businesses will perform over time. Wilson’s next chapter is being written through those practical commitments. It is possible to trace the decisions without treating every announcement as an ending.

From Albion to Michigan, from Penn to GEMMABio and Franklin, the career has involved repeated changes of institution and responsibility. The 2024 departure stands out because it came after such a long stay. Wilson took decades of experience into a new arrangement, kept Philadelphia as his base and placed more of the commercial task inside the companies he helped create. The next page of the story has an operating budget.